Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $6 million versus the consensus estimate of $4.7 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
• Nike names former Pfizer CFO David Denton as new finance chief